GANX — Gain Therapeutics Balance Sheet
0.000.00%
- $60.62m
- $50.67m
Annual balance sheet for Gain Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 7.49 | 36.9 | 20.1 | 16.8 | 10.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.067 | 0.195 | 0.191 | 0.243 | 0.766 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 8.99 | 37.7 | 21.1 | 17.8 | 11.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.553 | 1.21 | 1.02 | 0.779 | 0.323 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 9.6 | 39 | 24.1 | 18.6 | 12.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.11 | 2.55 | 4.13 | 4.95 | 3.91 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3.4 | 4.17 | 5.22 | 6.03 | 4.78 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 6.2 | 34.8 | 18.9 | 12.6 | 7.34 |
Total Liabilities & Shareholders' Equity | 9.6 | 39 | 24.1 | 18.6 | 12.1 |
Total Common Shares Outstanding |